Nitec Pharma raises CHF24 million
This article was originally published in Scrip
Executive Summary
The Swiss pharmaceutical company Nitec Pharma has defied market conditions by raising CHF24 million ($21 million). This adds to the CHF32 million that it raised in a series B financing early last year, and it will use the money primarily to develop its lead product Lodotra (night-time release prednisone) for rheumatoid arthritis.